ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO136

Comparison between the Different Doses of Preoperative Calcitriol to Prevent Hungry Bone Syndrome after Parathyroidectomy in ESKD: A Randomized Controlled Clinical Trial

Session Information

  • CKD-MBD: Clinical
    October 24, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical

Authors

  • Thookhamme, Ompan, Phramongkutklao College of Medicine, Bangkok, Thailand
  • Inkong, Pitchamon, Phramongkutklao College of Medicine, Bangkok, Thailand
Background

The most common complication of parathyroidectomy in end-stage kidney disease (ESKD) is hungry bone syndrome (HBS), resulting in prolonged hospitalization. Administering calcitriol before surgery is one strategy for preventing these complications; however, limited studies on the recommended calcitriol dose. The study aims to compare the efficacy and safety of different doses of calcitriol in preventing hypocalcemia in end-stage kidney disease (ESKD).

Methods

ESKD patients on regular hemodialysis with renal hyperparathyroidism undergoing parathyroidectomy were randomly assigned to receive 4 mcg/day of calcitriol or 2 mcg/day for 3 days before surgery. The primary outcome was hungry bone syndrome, defined as severe hypocalcemia or hypocalcemia on day 7, and secondary outcomes included electrolyte disturbances and hospitalization length.

Results

28 ESKD patients who underwent parathyroidectomy were enrolled, 14 received 4 mcg and the other 14 received 2 mcg of calcitriol. The mean age was 47.11±11.47 years, the mean serum calcium was 10.56±0.78 mg/dL, and the mean serum parathyroid hormone was 1866±677.62 pg/mL. The incidence of HBS was 62.5%, occurring in 5 (38.5%) and 10 (90.1%) participants in the high and low calcitriol groups, respectively (p = 0.008). The incidence of severe hypocalcemia within 72 hours were 5 (35.7%) in high-dose and 7 (50%) in low-dose groups, respectively (p = 0.704). Other factors including hypophosphatemia and length of hospitalization were similar in both groups. No serious adverse events were reported.

Conclusion

4 mcg of calcitriol showed significant benefits in preventing hungry bone syndrome after parathyroidectomy compared to 2 mcg of calcitriol, without serious adverse effects.